Vanda Pharmaceuticals Inc. (VNDA): Price and Financial Metrics


Vanda Pharmaceuticals Inc. (VNDA): $9.67

-0.03 (-0.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VNDA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VNDA POWR Grades

  • Value is the dimension where VNDA ranks best; there it ranks ahead of 99.66% of US stocks.
  • VNDA's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • VNDA ranks lowest in Growth; there it ranks in the 18th percentile.

VNDA Stock Summary

  • VNDA's current price/earnings ratio is 51.25, which is higher than 90.05% of US stocks with positive earnings.
  • For VNDA, its debt to operating expenses ratio is greater than that reported by merely 9.62% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.19 for VANDA PHARMACEUTICALS INC; that's greater than it is for only 12.99% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VANDA PHARMACEUTICALS INC are MDRX, CMBM, NATI, RNWK, and THRM.
  • VNDA's SEC filings can be seen here. And to visit VANDA PHARMACEUTICALS INC's official web site, go to www.vandapharma.com.

VNDA Valuation Summary

  • In comparison to the median Healthcare stock, VNDA's EV/EBIT ratio is 300% higher, now standing at 32.
  • VNDA's EV/EBIT ratio has moved up 39.9 over the prior 200 months.

Below are key valuation metrics over time for VNDA.

Stock Date P/S P/B P/E EV/EBIT
VNDA 2022-09-23 2.1 1.1 49.7 32.0
VNDA 2022-09-22 2.1 1.1 49.9 32.1
VNDA 2022-09-21 2.1 1.1 49.7 32.0
VNDA 2022-09-20 2.1 1.1 51.1 33.0
VNDA 2022-09-19 2.1 1.1 50.6 32.6
VNDA 2022-09-16 2.1 1.1 51.3 33.1

VNDA Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 94.67%.
  • Its 5 year net cashflow from operations growth rate is now at 586.49%.
  • The year over year cash and equivalents growth rate now stands at -7.22%.
VNDA's revenue has moved up $123,074,000 over the prior 70 months.

The table below shows VNDA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 262.696 45.735 10.993
2022-03-31 266.205 59.067 18.072
2021-12-31 268.682 64.214 33.152
2021-09-30 268.316 56.909 34.264
2021-06-30 258.529 56.886 32.44
2021-03-31 252.837 61.875 31.501

VNDA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VNDA has a Quality Grade of B, ranking ahead of 90.12% of graded US stocks.
  • VNDA's asset turnover comes in at 0.483 -- ranking 88th of 682 Pharmaceutical Products stocks.
  • NEOG, CLVS, and AMRN are the stocks whose asset turnover ratios are most correlated with VNDA.

The table below shows VNDA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.483 0.904 0.107
2021-06-30 0.479 0.904 0.105
2021-03-31 0.482 0.904 0.107
2020-12-31 0.486 0.906 0.086
2020-09-30 0.484 0.904 0.073
2020-06-30 0.493 0.900 0.085

VNDA Price Target

For more insight on analysts targets of VNDA, see our VNDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.00 Average Broker Recommendation 1 (Strong Buy)

VNDA Stock Price Chart Interactive Chart >

Price chart for VNDA

VNDA Price/Volume Stats

Current price $9.67 52-week high $21.44
Prev. close $9.70 52-week low $9.24
Day low $9.45 Volume 423,500
Day high $9.71 Avg. volume 509,120
50-day MA $10.48 Dividend yield N/A
200-day MA $11.83 Market Cap 546.94M

Vanda Pharmaceuticals Inc. (VNDA) Company Bio


Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. The company was founded in 2002 and is based in Washington, the District of Columbia.


VNDA Latest News Stream


Event/Time News Detail
Loading, please wait...

VNDA Latest Social Stream


Loading social stream, please wait...

View Full VNDA Social Stream

Latest VNDA News From Around the Web

Below are the latest news stories about VANDA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VNDA as an investment opportunity.

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company will participate in the H.C. Wainwright Global Investment Conference in New York City on Wednesday, September 14, 2022. A corporate presentation is scheduled for 8:30 a.m. Eastern Time.

Yahoo | September 8, 2022

VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice of opportunity for an FDA hearing on Vanda's Supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) to treat jet lag disorder.

Yahoo | September 7, 2022

Shareholders in Vanda Pharmaceuticals (NASDAQ:VNDA) are in the red if they invested five years ago

For many, the main point of investing is to generate higher returns than the overall market. But every investor is...

Yahoo | September 4, 2022

Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 3, 2022

Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2022.

Yahoo | August 3, 2022

Read More 'VNDA' Stories Here

VNDA Price Returns

1-mo -5.66%
3-mo -9.96%
6-mo -18.05%
1-year -43.97%
3-year -27.78%
5-year -46.13%
YTD -38.37%
2021 19.41%
2020 -19.93%
2019 -37.20%
2018 71.91%
2017 -4.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8383 seconds.